Introduction
Gliomas are the most common primary tumors of the brain that arise from astrocytes and their precursors, and are classified into four malignancy grades (Rasheed et al., 1999; Holland, 2000; Prados and Levin, 2000; Maher et al., 2001; Wechsler-Reya et al., 2001) . Glioblastoma multiforme (GBM), grade IV is the most frequent and aggressive glioma, with a median survival of 9 -12 months, despite complete surgical resection followed by radiation and chemotherapy (Rasheed et al., 1999; Holland, 2000; Prados and Levin, 2000; Maher et al., 2001; WechslerReya et al., 2001) . It is the third leading cause of cancer-related deaths in adolescents and adults in the United States (Levin et al., 1997) . GBM may be progressive arising from lower-grade gliomas, or it may arise de novo (Rasheed et al., 1999; Holland, 2000; Prados and Levin, 2000; Maher et al., 2001) . De novo GBM develops in older patients with prevalent gain-offunction mutations or amplification of the EGFR gene and loss-of-function mutations in the INK4a/ARF and PTEN genes (Libermann et al., 1985; Li et al., 1997; Steck et al., 1997; Ivanchuk et al., 2001) . Loss-of function mutations in the p53 gene are more common in the progressive form of GBM that usually occurs in young patients (Ichimura et al., 2000) . Amplification of the CDK4 and the MDM2 genes and inactivation of the Rb gene are also found in GBM, albeit at low frequency (Reifenberger et al., 1993; Schmidt et al., 1994; Wechsler-Reya et al., 2001) . Two of the 'mission critical' phenotypes that are always associated with these genetic alterations in GBM are deregulation of cell cycle progression and resistance to apoptosis (Evan and Vousden, 2001) . Recent studies reveal that Stat3, a latent transcription factor upon activation by aberrant cytokine or growth factor signaling, acts as a suppressor of apoptosis in a number of cancers, including multiple myeloma, head and neck squamous cell carcinoma, breast carcinoma, leukemia and lymphomas (Catlett-Falcone et al., 1999; Bowman et al., 2000; Grandis et al., 2000; Schuringa et al., 2000; Badache et al., 2001; Epling-Burnette et al., 2001) . Furthermore, a mutant Stat3 with two cysteine substitutions in the SH2 domain that dimerizes spontaneously through disulphide bonds, is capable of inducing cellular transformation and tumor formation in nude mice by binding to DNA and activating transcription (Bromberg et al., 1999) .
Stat-family proteins function as intracellular effectors for cytokine and growth factor-dependent transcrip-tional activation of genes that control proliferation, differentiation and apoptosis of a variety of normal as well as transformed cell types (Bowman et al., 2000; Hirano et al., 2000) . Stat3 is ubiquitously expressed in mammalian cells and activated by the IL-6-family of cytokines that include IL-6, CNTF, OSM and LIF, and by the growth factors EGF and PDGF in target cells that express the cognate receptors (Hirano et al., 1990 (Hirano et al., , 2000 Kishimoto et al., 1994; Heinrich et al., 1998; Bowman et al., 2000) . Src-family of tyrosine kinases also activates Stat3 in transformed fibroblasts (Yu et al., 1995; Bowman et al., 2000) .
GBM cells secrete IL-6 and respond to it (Van Meir et al., 1990; Goswami et al., 1998; Rolhion et al., 2001; Tchirkov et al., 2001) . However, little is known about IL-6-dependent signal transduction and subsequent gene expression in the pathogenesis of GBM. Here we demonstrate that Stat3 is constitutively activated in GBM tumors and cell lines, which is in part attributable to the autocrine action of IL-6. Inhibition of constitutive Stat3 activation induces apoptosis and inhibits proliferation of GBM cells by reducing the steady-state level of Bcl-2-family of anti-apoptotic proteins.
Results

Stat3 is constitutively activated at high frequency in human GBM tumors and cell lines
While investigating the regulation of IL-4 signaling in GBM cell lines we found that Stat3 was constitutively activated in a number of GBM cell lines (Figure 1a) , and IL-4 further induced the activation of Stat3 (Rahaman and Haque, unpublished data) . This observation prompted us to examine if Stat3 was constitutively activated in GBM tumor tissues and whether activated Stat3 regulated the growth of GBM cells. A high-affinity sis (PDGF)-inducible element (hSIE) derived from the c-fos promoter binds to a protein complex of three sis-inducible factors (SIFs), termed SIF-A (Stat3 homodimers), SIF-B (Stat1-Stat3 heterodimers) and SIF-C (Stat1 homodimers) (Wagner et al., 1990; Catlett-Falcone et al., 1999) . Using the radiolabeled SIE probe in an electrophoretic mobility shift assay (EMSA), we found that SIF was constitutively activated at varying levels in 18 out of 19 (94.7%) GBM tumors, while normal human astrocytes (NHA), tumor-adjacent normal tissue (CCF50) and Figure 1 High frequency of Stat3 activation in human GBM tumors and cell lines. (a) GBM cell lines (A172, D54, T98G and U251) and normal human astrocytes (NHA) were grown in serum free medium for 24 h, and whole cell extracts (WCE) prepared. WCE containing 10 mg of protein were subjected to EMSA using 0.2 ng of 32 P-labeled hSIE probe that binds to sis-inducible factor SIF. (b) WCE was prepared from frozen GBM tumor tissues, white matter (WM), and normal tissue adjacent to tumor (CCF50). Numbers in parentheses indicate micrograms of protein used in EMSA. WCE derived from NHA and U251 cells were used as controls. EMSA was performed as described above. (c) Antibodies specific for Stat1, Stat3 and Stat5 (negative control) were incubated with WCE derived from GBM tumors CCF54, CCF88 and CCF133, GBM cell lines D54 and U251, in EMSA binding buffer for 20 min at room temperature prior to addition of radiolabeled SIE probe. EMSA was performed as described above. While antiStat3 antibody shifted up the major SIF complexes, anti-Stat1 antibody inhibited the SIE-SIF complex formation in both GBM tumors and cell lines white matter (WM), collected from patients with epilepsy, contained very low levels of or no activated SIF (Figure 1b) . Predominant complexes present in GBM tissues were SIF-A and SIF-B.
To verify Stat components of SIF complexes present in GBM tumors and cell lines we performed EMSA-supershift analyses by using antibodies that were specific for Stat1, Stat3 and Stat5 (negative control). SIF-A containing Stat3-homodimers was found to be predominant in CCF54, CCF88 and CCF133 tumors and in U251 and D54 cell lines (Figure 1c ). Stat1-homodimers (SIF-C) were also present at low levels or absent in most GBM tumors. These results demonstrate a high incidence of constitutive activation of Stat3 in both GBM tumors and cell lines.
To directly demonstrate the presence of activated Stat3 in the GBM tumor tissues we stained tumor (CCF54 and CCF133) sections (5 mM), U251 cells and NHA with Stat1-and Stat3-specific anti-phosphotyrosine antibodies. Sections from CCF50 and WM, having little or no activated SIF, were stained as negative controls. Phospho-Stat3 immunoreactivity was strongly positive in all tumor sections and U251 cells (Figure 2 ). By contrast, very little immunoreactivity was observed in NHA, as evident by poor nuclear staining (Figure 2 ). Similar negative staining was observed in CCF50 and WM. Furthermore, all the tumor sections were poorly stained with anti-phosphoStat1 antibody (data not shown). The staining of tumor sections and cells in the absence of binding of primary antibody, served as negative controls (data not shown). The immunohistochemistry results clearly demonstrate that constitutively activated Stat3 is present in GBM tumors and U251 cell line, which was consistent with the EMSA data ( Figure 1 ).
Autocrine action of IL-6 induces the constitutive activation of Stat3 in GBM cells Activated Stat3 content of NHA was significantly lower than that of GBM cell lines or tumor tissues. This was not due to the absence of Stat3 expression in NHA. Western analysis revealed that Stat3 protein was expressed in NHA at levels comparable with that in GBM cell lines (Figure 3a) . Moreover, IL-6 induced the activation of Stat3 in NHA as it did (over the basal level) in U251 cells, indicating that the observed presence of low levels or absence of Stat3 activation in NHA is not due to a defect in the intracellular IL-6 signaling pathways (Figure 3b ).
GBM cells secrete IL-6 both in vivo and in vitro (Van Meir et al., 1990; Goswami et al., 1998; Rolhion et al., 2001; Tchirkov et al., 2001) . To address if the autocrine IL-6 action was responsible for the persistent activation of Stat3 in GBM, U251 cells were incubated with saturating concentration of a neutralizing antibody against IL-6 for 24 and 48 h, and Stat3 activation was measured by EMSA. Activation of Stat3 in the U251 cell line was significantly (60 -70%) blocked by the neutralizing antibody, suggesting that the constitutive activation of Stat3 is, in part, attributable to the autocrine action of IL-6 in this cell line (Figure 3c ).
AG490 inhibits the constitutive activation of Stat3 in U251 cells
IL-6 activates Stat3 through the activation of gp130 that is associated with Jak1, Jak2 or Tyk2 (Lutticken et al., 1994; Stahl et al., 1994) . We found that treatment of U251 cells with the Jak-specific kinase inhibitor AG490 (Meydan et al., 1996) blocked the constitutive activation of Stat3 in a dose-dependent (data not shown) and time-dependent fashion, with the complete inhibition occurring by 72 h treatment ( Figure 4a ). As expected, phosphorylation of tyrosine 705 of Stat3 was inhibited by AG490 in dose-and time-dependent fashions without affecting the steady-state levels of endogenous Stat3 in the U251 cell line (Figure 4b ). These data indicate that the majority of constitutive activation of Stat3 in U251 cells is catalyzed by the activity of gp130-associated Jaks.
Effects of AG490 on the proliferation and survival of U251 cells
Emerging evidence suggests that the constitutive activation of Stat3 directly contributes to oncogenesis by promoting proliferation and/or by suppressing apoptosis (Bromberg et al., 1999; Catlett-Falcone et al., 1999) . We noted a significant reduction in cell viability when U251 cells were treated with 25 -50 mM AG490 for 72 h compared with NHA, as measured by MTS assay (Figure 5a ). In a variety of cancer cells activated Stat3 induces the expression of a number of bcl-2-family of anti-apoptotic genes that include bcl-2, bcl-X and mcl-1 (Fukada et al., 1996; Catlett-Falcone et al., 1999; Hirano et al., 2000; Epling-Burnette et al., 2001 ). We measured steady-state levels of these three proteins in AG490 treated U251 cells by Western analyses. AG490 reduced the steady-state level of Bcl-X L protein in dose-and timedependent fashions (Figure 5b ), which correlated with AG490-mediated inhibition of Stat3 activation in U251 cells. Steady-state levels of Bcl-2 and Mcl-1 were also reduced by AG490 treatment of U251 cells, albeit to lesser extents than that of Bcl-X L ( Figure 5b ).
We examined effects of AG490 treatment on apoptosis of U251 cells by Annexin V staining followed by FACS analysis. We found that the percentage of apoptotic U251 cells increased from 29.2% (DMSO, vehicle control) to 39.0, 57.3 and 69.7% with 12.5, 25 and 50 mM concentrations of AG490 respectively by 48 h (Figure 5d ). Poly (ADP-ribose) polymerase (PARP), a 116 kDa nuclear enzyme is important for cells to maintain viability, and is inactivated by caspase-mediated cleavage into 24 and 89 kD fragments in apoptotic cells (Pieper et al., 1999) . U251 cells were treated with varying concentrations of AG490 (12.5 -50 mM) for 48 and 72 h in serum-free medium, and cell lysates prepared were subjected to Western analysis using anti-PARP antibody. AG490 treatment induced dose-and time-dependent cleavage of PARP in U251 cells (Figure 5c ). Taken together, these data suggest that AG490 reduces steady-state levels of Bcl-2-family of pro-survival proteins with the concomitant induction of apoptosis in U251 cells.
Dominant negative mutant Stat3 inhibits the constitutive activation of Stat3 with a concomitant suppression of proliferation and survival of U251 cells
To further address the role of constitutively activated Stat3 in proliferation of GBM cells, a dominant negative mutant Stat3 construct (termed DN-Stat3) that has a phenylalanine substitution at position 705 was stably expressed in the U251 cells. IL-6 induces the phosphorylation of tyrosine 705 of the wild-type Stat3 (Yu et al., 1995; Bromberg et al., 1999; Catlett-Falcone et al., 1999; Hirano et al., 2000) . DN-Stat3 inhibits IL-6-mediated activation of wild-type Stat3 (Zhong et al., 1994; Kaptein et al., 1996) . Two representative U251 stable clones C#11 and C#19 expressing the DN-Stat3 exhibited marked reduction of constitutive activation of Stat3 (Figure 6a) . Surprisingly an overactivation of Figure 2 Phospho-Stat3 immunostaining of GBM tumors and cell lines. GBM tumors (CCF54 and CCF133), tumor-adjacent normal tissue (CCF50), white matter (WM), normal human astrocytes (NHA) and U251 cell line were used for immunostaining. Anti-phospho-Stat3 (tyrosine 705 ) antibody was employed for immuno-peroxidase staining (Vector Laboratories, ABC kit with DAB substrate). An intense and widely spread nuclear staining for phospho-Stat3 (206 magnification) in the entire tumor sections (n=6) and U251 cells was detected. Phospho-Stat1 (tyrosine 701 ) positive cells were also detected in tumor sections (data not shown). Little or no immunostaining was detected in NHA and CCF50 or white matter (WM) sections (negative control). All the sections were counterstained by hematoxylin (blue) Stat1 was observed in these two Stat3-DN clones. However, the mechanism for the DN-Stat3-mediated over-activation of Stat1 is not known. Expression of the mutant Stat3 in the stable clones was confirmed by RT -PCR (Figure 6b ).
To determine effects of expression of DN-Stat3 on the growth of U251 cells, C#11, C#19, parental U251 and vector control stable clones were cultured under identical conditions, and the cell proliferation was examined at different time points. The proliferation of C#11 and C#19 cells was significantly suppressed compared with that of the parental U251 and vector control clones (Figure 6c ). Subsequently steady-state levels of Bcl-2, Bcl-X L and Mcl-1 were determined in these stable cell lines. Both C#11 and C#19 were found to contain lesser amounts of Bcl-X L and Mcl-1 than the control cells, while Bcl-2 level remained almost unchanged (Figure 6d ). In addition, annexin V staining of the DN-Stat3 expressing clones clearly revealed an increased number of apoptotic cells compared with the control cells (Figure 6e ). Taken together these results suggest that persistently activated Stat3 attributes to the maintenance of the steady-state levels of both Bcl-X L and Mcl-1 that are involved in the survival of U251 cells.
Discussion
Stat3 is normally activated by the IL-6-family of cytokines and other growth factors that include EGF and PDGF (Heinrich et al., 1998; Bromberg et al., 1999; Catlett-Falcone et al., 1999 , Hirano et al., 2000 . Stat activation by cytokines and growth factors, in general, is limited in both magnitude and duration by the action of multiple negative regulators in the cell (Haque et al., 2000) . However, persistent activation of Stat3 occurs in a number of human cancers (CatlettFalcone et al., 1999; Bowman et al., 2000; Grandis et al., 2000; Schuringa et al., 2000; Badache et al., 2001; Epling-Burnette et al., 2001) . This may result from the constitutive activation of cytokine-or growth factor receptors either by their continuous interaction with Figure 3 Stat3 activation is in part, attributable to an autocrine action of IL-6. (a) Western blot analysis was performed to examine steady-state levels of Stat3 expression in GBM cell lines (D54, T98G, U87-MG and U251) and normal human astrocytes (NHA). Cell lysates containing 70 mg of protein were resolved in a 10% SDS-polyacrylamide gel and derived blot was probed with anti-Stat3 antibody. (b) Stat3 activation by IL-6 was determined in U251 cells and normal human astrocytes (NHA). Cells grown in serum-free medium for 24 h were treated with IL-6 (25 ng/ml) for 30 min or left untreated as control. Whole cell extracts (WCE) were prepared. WCE containing 10 mg of protein were subjected to EMSA using 0.2 ng of radiolabeled hSIE probe that binds to SIF. Activated Stat3 was the major component of SIF in these cells (Figure 1 ). (c) U251 cells were incubated in serum-free medium containing IL-6 neutralizing antibody (1 mg/ml) for 24 and 48 h or control IgG (1 mg/ml) for 48 h. WCE containing 10 mg of protein were subjected to EMSA as described above 3 cells/well) were seeded in a 96-well plate and grown in the normal medium for 24 h. AG490 at varying concentrations (12.5 -50 mM) was then added to cells in fresh medium containing 5% serum, and cells were incubated for 96 h. Cells were then washed with PBS and incubated in 100 ml serum-free medium plus 20 ml of 'Cell-Titer 96 Aqueous One Solution' reagent that contained the tetrazolium compound MTS and the electron coupler PES, at 378C for 90 min. Cell viability was assessed by the bioreduction of MTS by measuring absorbance at 490 nm with a 96-well plate reader. Error bars represent standard deviations (n=5). Statistical significance was calculated by the student t-test. Survival of AG490 treated U251 cells was significantly low compared with untreated control (*P50.005, **P50.001). (b) AG490 reduced steady-state expression of Bcl-X L , Bcl-2, and Mcl-1 in U251 cells. Cells were treated with varying concentrations (12.5 -50 mM) AG490 for the indicated time points. Seventy micrograms of cell lysate protein were used for Western blot analyses using antibodies against Bcl-X L , Bcl-2 and Mcl-1. Membranes were reprobed with anti-actin antibody to ensure equivalent loading. The bottom panel shows a representative Western blot for actin. (c) U251 cells were treated with the indicated concentration of AG490 or DMSO for 48 and 72 h in 5% serum to study PARP cleavage. Seventy micrograms of cell lysate protein were used for Western blot analyses using anti-PARP antibody that recognizes full-length as well as the 89 kD fragment. Membrane was reprobed with anti-actin antibody to ensure equivalent loading. C#11 and DN-Stat3 C#19), one stable clone expressing wild-type Stat3 transgene (designated as Stat3-TG) and vector control cell lines were grown in serum-free medium and harvested to prepare whole cell extracts (WCE). WCE containing 15 mg of protein were subjected to EMSA using 0.2 ng of radiolabeled SIE probe as described in Figure 1 . The gel was run for a relatively longer time period to resolve all three SIF complexes as indicated by arrowheads. (b) Expression of DN-Stat3 and Stat3-TG in stable clones was confirmed by RT -PCR with the primers described in Materials and methods. An 1.1 Kb amplified PCR product from the above cell lines was detected in a 0.7% agarose gel after ethidium bromide staining. (c) Proliferation of DN-Stat3 (C#11 and C#19), vector control, and parental U251 cells was determined. 2000 -4000 cells from each clone were plated into 96-well plates in quadruplicate in DMEM with 10% FCS. Serum concentration was reduced from 10% to 1% after 24 h. Cell number was counted at different time points by using MTS assay according to the manufacturers' instructions (Promega MTS assay kit) by measuring absorbance at 490 nm with a 96-well plate reader. Error bars represent s.d. of quadruplicate samples. (d) C#11, C#19, vector control, and parental U251 cells (5610 5 ) were grown in DMEM containing 10% FCS. After 24 h serum concentration in the medium was reduced to 1% and cells were harvested after 144 h. Seventy micrograms of cell lysate protein were used for Western blot analyses using antibodies against Bcl-X L , Bcl-2 and Mcl-1. Membranes were reprobed with anti-actin antibody to ensure equivalent loading (bottom panel). (e) C#11, C#19, vector control, and parental U251 cells (5610 5 ) were grown in DMEM containing 10% FCS. After 24 h serum concentration in the medium was reduced to 1% and cells were grown for 144 h. Five microlitres of Annexin V-FITC were added to 1610 6 cells in a tube and allowed to incubate at room temperature for 15 min in the dark. 1610 4 cells per experimental condition were analysed for fluorescence on a FACScan using Cell Quest software. Data shown are mean+s.e.m. of triplicate determinations in three independent experiments are quite common in human cancers including gliomas (Libermann et al., 1985; Leonard and O'Shea, 1998; Rasheed et al., 1999; Holland, 2000; Prados and Levin, 2000; Wechsler-Reya et al., 2001; Maher et al., 2001) .
We show herein that unlike NHA, more than 90% of human GBM tumors and all GBM cell lines examined contain persistently activated Stat3 (Figures 1 and 2 ). Recent studies demonstrate that the IL-6 gene is amplified and overexpressed in GBM tumors and cell lines (Van Meir et al., 1990; Goswami et al., 1998; Rolhion et al., 2001; Tchirkov et al., 2001) . Activated Stat3 content is reduced by *70% when U251 cells are treated with a saturating concentration of IL-6 neutralizing antibody (Figure 3 ) that completely blocks IL-6-mediated activation of Stat3 in 293T cells in a control experiment (data not shown). However, the Jakspecific tyrosine kinase inhibitor AG490 at a concentration of 50 mM completely abrogates Stat3 activation in U251 cells by 72 h suggesting that 50 mM AG490 also inhibits IL-6-independent activation of Stat3 in U251 cells. A recent study has shown that astrocytomas produce OSM and LIF that use Jaks for Stat3 activation (Lilja et al., 2001) . Therefore, it remains to be examined if U251 and other GBM cells secrete OSM or LIF, and express their cognate receptors. Another study has demonstrated that Stat3 is constitutively activated in the GBM cell line A172, but not in T98G and U343-MG cell lines, while OSM induces Stat3 activation in all three cell lines (Halfter et al., 2000) . Although we have not examined Stat activation in U343-MG cells, our data clearly demonstrate that T98G cell line contains a high level of persistently activated Stat3 (Figure 1 ). This discrepancy may represent clonal variation of T98G cell line used in these investigations. Persistently activated Stat3 content is also found to be varying among different GBM primary tumor specimens (Figure 2 ). This may be due to heterogeneity of cells in GBM tumor specimens. Variations may also result from the differential turnover of Stat3 activation in different tumors, which may also be true for the GBM cell lines. A recent study shows that PTEN, which is deficient in *30% of the GBMs (Wechsler-Reya et al., 2001) , has the potential of dephosphorylating activated Stat3 in human papillopmavirus-infected cells (Sun et al., 2002) . Moreover, level of signal input may vary from tumor cell to tumor cell due to differential activation profile of the autocrine-loop, which in turn depends on cell surface expression of IL-6 receptor subunits as well as on IL-6 secretion by GBM cells.
Our preliminary data reveal that blocking of EGFR but not PDGFR or Src kinase activity by pharmacological compounds markedly reduces the constitutive activation of Stat3 in U251 cells (data not shown) suggesting EGFR activation in part, may contribute to the constitutive activation of Stat3.
Several studies have suggested that there are two distinct pathways that lead to the activation of the apoptotic machinery, one involving cell surface death receptors and the other involving Bcl-2-related proteins via the release of mitochondrial cytochrome c (Evan and Littlewood, 1998; Thornberry and Lazebnik, 1998) . Despite the expression of a number of death receptors that include Fas, DR4 and DR5, some GBM cell lines manage to evade the death receptor-mediated apoptosis (Rieger et al., 1998) . Studies have indicated that overexpression of the bcl-2 gene is sufficient to block Fas/FasL-mediated apoptosis in glioma cells (Weller et al., 1995) . We found that Bcl-2, Bcl-X L and Mcl-1 proteins are expressed in U251 (Figure 5c ) and other GBM cells (data not shown). Steady-state levels of these proteins are markedly reduced in AG490-treated U251 and T98G cells (data not shown), indicating that the expression of these anti-apoptotic genes are regulated by the constitutive activation of Stat3 in GBM cells. A Stat3-responsive enhancer element is identified in the promoters of bcl-X and mcl-1 gene that are transcriptionally controlled by activated Stat3 in human cancer cells, while bcl-2 gene is an indirect target for activated Stat3 (Fukada et al, 1996; Catlett-Falcone et al., 1999; Epling-Burnette et al., 2001) . In addition, inactivation of Stat3 cells by AG490 or DN-Stat3 induces apoptosis in U251 cells (Figures 5 and 6 ). These data suggest that activated Stat3 suppresses apoptosis of GBM cells that is in part mediated by up-regulating the expression of the bcl-2-family of anti-apoptotic genes that include bcl-2, bcl-X and mcl-1. We also show that cell number is significantly reduced by inactivation of Stat3 in AG490-treated as well as DN-Stat3-expressing U251 cells as measured by MTS assay (Figures 5 and 6 ). Activated Stat3 has previously been shown to increase the proliferation of a number of cancer cells including the GBM cell line GL-15 (Paillaud et al., 2002) . Although the extent of MTS reduction reflects the number of viable cells under the assay conditions that are associated with significant apoptosis of cells, it is difficult to assess to what extent cell division is compromised by Stat3 inactivation in U251 cells. Clearly further studies are required to address whether the AG490-or DN-Stat3-mediated decrease in number of U251 cells is due to decreased mitogenic signals or increased apoptosis.
Signal transduction pathways are likely essential therapeutic targets that are aberrantly operated in GBM cells. Our findings clearly indicate that Stat3 signaling significantly contributes to the pathogenesis of GBMs. While this manuscript was in preparation Schaefer et al. (2002) have reported that constitutively active Stat3 is predominantly localized in endothelial cells of glioma and medulloblastoma tumors and induces the expression of vascular endothelial growth factor gene. Therefore, targeting Stat3 signaling along with other potential signaling pathways may improve the therapeutic outcomes for this most lethal and difficult-to-treat form of human cancer.
Materials and methods
Tissue collection and cell culture GBM tumor samples, tumor-adjacent normal tissue (CCF 50) and white matter (WM) derived from patients with epilepsy, were collected from Cleveland Clinic Foundation (CCF) Tumor Bank following NIH and institutional guidelines. GBM cell lines U251, T98G, A172, U87-MG and D54 were cultured in DMEM (GIBCO-BRL, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal calf serum (Life Technologies Inc, Rockville, MD, USA), 2 mM glutamine, and 50 mg/l of penicillin and streptomycin. Normal human astrocytes were obtained and maintained in specific growth medium AGM bullet kit from CloneticsBioWhittaker (Walkersville, MD, USA).
Electrophoretic mobility shift assay (EMSA)
Cells were harvested and whole cell extracts (WCE) prepared as described (Haque et al., 1997; Rahaman et al., 2002) . Electrophoretic mobility shift assay (EMSA) was performed using 10 -15 mg of WCE proteins and 0.2 ng of 32 P-labeled high affinity SIE probe (top strand: 5'-TCGACATTTCCCG-TAAATC-3') derived from the c-fos gene promoter (Wagner et al., 1990; Catlett-Falcone et al., 1999) . For EMSAsupershift WCE were preincubated with polyclonal antibodies specific for Stat1, Stat3, and Stat5 proteins (Santa Cruz Biotechnology, Santa Cruz, CA, USA) prior to the addition of radiolabeled probe for 20 min at room temperature.
Immunohistochemistry
Frozen GBM tumor samples, white matter (WM), and tumor adjacent normal tissue (CCF50) were sectioned (5 mm) and immunostained employing standard techniques (ABC method, Vector Laboratories, Burlingame, CA, USA). U251 cells and NHA were grown on coverslips for immunostaining. Polyclonal anti-phospho-Stat3 (Tyr705) and phospho-Stat1 (Tyr701) antibodies (New England Biolabs, Beverly, MA, USA) were employed as primary antibodies for immunoperoxidase staining (Vector Laboratories, ABC kit with DAB substrate). All the sections and cells were counterstained with hematoxylin. Staining of sections and cell lines without primary antibody was used as negative control.
Western blot analysis
Western blot analyses were performed as described (Haque et al., 1997; Rahaman et al., 2002) . Anti-Stat3 antibody was obtained from Zymed Laboratories Inc. (San Francisco, CA, USA). Antibodies for Phospho-Stat3 and PARP were purchased from Cell Signaling. (Beverly, MA, USA), and antibodies for Bcl-2, Mcl-1 and Actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Bcl-X L antibody was from Transduction Laboratories, (Franklin Lakes, NJ, USA).
Cell viability assay
U251 and NHA cells (12 000 cells/well in 100 ml medium) in DMEM and AGM respectively were incubated for 96 h in the absence or in the presence of varying concentrations of AG490, and cell viability was assessed by the bio-reduction of a tetrazolium compound (Promega MTS assay kit, Son Luis, CA, USA) by measuring absorbance at 490 nm with a 96 well-plate reader.
Flow-cytometry
Following treatment with AG490 or DMSO (vehicle), cells were detached by mild trypsinization, counted and pelleted (1000 r.p.m. for 5 min). Cell pellets were washed once with PBS and once in Annexin V binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ). 1610 6 cells were transferred to a tube and 5 ml of Annexin V-FITC was added per tube and allowed to incubate at room temperature for 15 min in the dark. An experimental condition of 1610 4 cells were analysed for fluorescence on a FACScan using the Cell Quest software.
Transfection of cells
U251 cells were transfected with a dominant-negative Stat3, wild-type Stat3 (obtained from Dr Koichi Nakajima, Osaka University Medical School, Osaka, Japan), and empty vector along with a puromycin resistant plasmid by using LipofectAMINE (Life Technologies, Inc, Rockville, MD, USA) according to the manufacturer's instructions. Stable clones were selected by puromycin (0.5 mg/ml) for 3 -4 weeks as described (Rahaman et al., 2002) .
RT -PCR
Total RNA was isolated from cells using TRIzol reagent according to the manufacturer's protocol (Life Technologies, Inc., Rockville, MD, USA). One microgram of total RNA was reverse-transcribed in a final volume of 50 ml using RT -PCR kit (Invitrogen, Carlsbad, CA, USA) according to manufacturer's instructions. The primers used were 5'-GTA-CCCATACGACGTCCCAG-3' and 5'-CCAGCAACCTGA-CTTTCGTG-3'.
Cell proliferation assay
For cell proliferation assay 2000 -4000 cells from each clone were seeded into 96-well plates in quadruplicate in DMEM with 10% FCS, which was reduced to 1% after 24 h. Cell number was counted at different time points by using MTS assay according to the manufacturer's instructions (Promega MTS assay kit, Son Luis, CA, USA) by measuring absorbance at 490 nm with a 96-well plate reader.
